Syndax Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
Syndax Pharmaceuticals, Inc. (SNDX) reported Amortization of Debt Issuance Costs of $359.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $303.00K, a 450.91% increase year-over-year.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $56.00K, a 50.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was -$1.00K, a 103.33% decline year-over-year.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $62.00K.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2025 was $228.00K, a 660.00% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2024 was $30.00K.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2022 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $359.00K 10-Q · filed 2026-08-04 | $358.00K derived: sum of 3 quarters · filed 2026-08-04 | $420.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $56.00K 10-Q · filed 2026-04-30 | $55.00K derived: sum of 2 quarters · filed 2026-04-30 | $117.00K derived: sum of 3 quarters · filed 2026-04-30 | $172.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $61.00K derived: sum of 2 quarters · filed 2026-02-26 | $116.00K derived: sum of 3 quarters · filed 2026-08-04 | $228.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $117.00K derived: sum of 2 quarters · filed 2026-08-04 | $229.00K 10-Q · filed 2025-11-03 | $259.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $167.00K 10-Q · filed 2026-08-04 | $197.00K derived: sum of 3 quarters · filed 2026-08-04 | $197.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $112.00K 10-Q · filed 2026-04-30 | $142.00K derived: sum of 2 quarters · filed 2026-04-30 | $142.00K derived: sum of 3 quarters · filed 2026-04-30 | $142.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.00K derived: sum of 2 quarters · filed 2026-02-26 | $30.00K derived: sum of 3 quarters · filed 2026-02-26 | $30.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |